ID: high_molecular_weight_hyaluronic_acid
Aliases: HMW hyaluronic acid, high molecular weight HA
Type: compound
Route/form: route not curated
Status: supplement_or_research
Evidence level: preclinical
Best data tier: non-human experimental
Support scope: non-human/mechanistic, review/regulatory
Source types: preclinical, review
Linked sources: 3
Broad outcomes: Gut / immune / inflammation
Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.
Targets / mechanism
- intestinal barrier
- gut microbiota remodeling
- colitis inflammation
Optimization domains
- gut health
- colitis
- barrier function
- microbiome
Research basis
- A 2026 preclinical study reports protection against colitis through microbiota remodeling and barrier restoration.
- Useful gut-barrier node for separating mechanistic animal claims from human GI evidence.
Limits, risks, and missing evidence
- Colitis model results do not establish benefit in human IBD, IBS, or general gut health.
- Molecular weight, purity, route, and dose are central to interpretation.
Risk flags
- preclinical only
- formulation specific
- limited human data
- microbiome claim
Linked papers, labels, and reviews
- High-molecular weight hyaluronic acid protects against colitis by remodeling microbiota and restoring barrier function
preclinical / sciencedirect_hmw_ha_colitis_2026
Molecular-weight-dependent hyaluronic acid colitis model. - Hyaluronan-induced alterations of the gut microbiome protects mice against Citrobacter rodentium infection and intestinal inflammation
preclinical / pubmed_hyaluronan_microbiota_colitis_2021
Mouse microbiota-transfer and colitis/infection evidence for HA-gut-microbiome immune effects. - Hyaluronan: A Neuroimmune Modulator in the Microbiota-Gut Axis
review / pmc_hyaluronan_gut_axis_review_2022
Review of HA interactions with luminal bacteria and host gut neuroimmune responses; useful context for gut-barrier claims.